Lisbon, November 30, 2013

Honorary President: Prof. Doutor Miguel Carneiro de Moura

Scientific Committee: Prof. Doutor Miguel Carneiro de Moura Prof. Doutor José Velosa Prof. Doutor Rui Sarmento e Castro Dr. Eliav Barr

PROGRAMA 9:15 - 9:30 Welcome and Opening Remarks Prof. Doutor Miguel Carneiro de Moura

9:30 - 10:30 The Burden of Disease Chairman – Prof. Doutor Armando Carvalho

Benefits of HCV Treatment (Prevention of Complications) Dr. Filipe Calinas

Cost-effectiveness of Boceprevir - the Portuguese Data Dr. Pedro Laires

Q&A

10:30 - 11:00 State of the Art Lecture I Chairman – Prof. Doutor José Velosa

Predictive Factors of Response Prof. Doutor Massimo Colombo

11:00 - 11:30 Coffee Break

11:30 - 12:30 Treat or Wait - Risks and Benefits Chairman – Prof. Doutor Miguel Carneiro Moura

Defering Treatment Dra. Isabel Pedroto

Treat Now Dr. Christophe Hezode

Q&A

12:30 - 14:00 Lunch

14:00 - 14:30 State of the Art Lecture II Chairman – Prof. Doutor Rui Sarmento e Castro

Oral Regimens Dra. Karin Hagen

14:30 - 16:30 Optimizing Treatment to Improve Patient Outcomes Chairman – Prof. Doutor Guilherme Macedo

Difficult-to-Treat Patients (Cirrhotic & Null-Responders) Prof. Doutora Fátima Serejo

Difficult-to-Treat Patients (Co-Infected) Dra. Manuela Doroana

Treatment Management (Drug Interactions & Adverse Events) Dra. Cristina Valente

Patient Management (My Experience with Boceprevir) Prof. Doutor Rui Marinho

Q&A

16:45 - 17:00 Closing Remarks Prof. Doutor José Velosa